Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. scores highest on Anchor (47) and lowest on Earnings (30). Its PosiPenta is 37.12 out of 100, weaker than most similar companies.
On the Penta Grid this week, Zentalis Pharmaceuticals, Inc. is Grid #628 of 837 in the Healthcare sector in United States, and Grid #3,140 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. | 37.12 | 34 | 30 | 35 | 39 | 47 |
| Larimar Therapeutics, Inc. | 37.40 | 32 | 44 | 24 | 42 | 46 |
| Lexeo Therapeutics, Inc. | 36.08 | 40 | 31 | 19 | 58 | 32 |
| Palisade Bio, Inc. | 52.20 | 74 | 43 | 39 | 66 | 40 |
| Utah Medical Products, Inc. | 79.49 | 58 | 90 | 95 | 82 | 72 |
| American Well Corporation | 54.33 | 40 | 40 | 85 | 67 | 39 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -1.09 |
| P/B ratio | 1.46 |
EEarnings
| Trailing EPS | ₹-185.64 |
| Forward EPS | ₹-168.71 |
NNitro
| Price | 201.74 |
| 52-week high | 658.27 |
| 52-week low | 114.79 |
| Fall from 52-week high | 69.4% |
TTorque
| Return on equity (ROE) | -66.75% |
| Debt-to-equity | 0.26 |
AAnchor
| Beta (price swings) | 1.94 |
| Market cap | ₹1,979 Cr |
| Insider holding | 21.85% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Zentalis Pharmaceuticals, Inc.'s PosiPenta score?
Zentalis Pharmaceuticals, Inc.'s PosiPenta is 37.12 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Zentalis Pharmaceuticals, Inc. stand on the Penta Grid?
On the Penta Grid this week, Zentalis Pharmaceuticals, Inc. is Grid #628 of 837 in the Healthcare sector in United States, and Grid #3,140 of 4,000 in United States.
Which PosiPenta pillar is strongest for Zentalis Pharmaceuticals, Inc.?
Anchor (stability and dividends), with a score of 47 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Zentalis Pharmaceuticals, Inc.?
Earnings (growth), with a score of 30 out of 100: weaker than most similar companies.
Has Zentalis Pharmaceuticals, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.37 points, from 33.75 to 37.12.
PositoAI is for research and education only and is not investment advice.